In today’s Pharmaceutical Executive Daily, Johnson & Johnson reaches an agreement with the Trump administration while ...

At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

Hayley Burgess SVP, Inovalon, touches on Specialty pharmacies grappling with surging drug complexity and costs while navigating fragmented data systems, access hurdles, and prior authorization demands ...

This also marks the second signification project for Johnson & Johnson in Wilson, as back in October 2024, the company ...

The executive spoke at the 44 th annual 2026 JP Morgan Healthcare Conference in San Francisco early on Monday, January 12.

Hayley Burgess SVP, Inovalon, touches on Specialty pharmacies grappling with surging drug complexity and costs while ...

Michael O' Rurke , CEO Re-Vana Therapeutics, discusses positioning Re-Vana as a long-term platform partner by leveraging its ...

PE: How can teams reduce patient burden without weakening their science? Schwab: Number one is lean trial design. We should ...

32 Biosciences revealed its plan to launch a $40 million Series A at this year’s J.P Morgan Healthcare conference, to advance ...

Johnson & Johnson continues its $55 billion investment in U.S. operations (first announced back in 2025), targeting ...

In the third part of her conversation with PharmExec, Trialynx founder and CEO Angela Schwab discusses the causes and ...

In today’s Pharmaceutical Executive Daily, the FDA moves to limit regulation of non-medical fitness wearables, industry ...